Literature DB >> 23809874

Six minute walk test in type III spinal muscular atrophy: a 12month longitudinal study.

E Mazzone1, F Bianco, M Main, M van den Hauwe, M Ash, R de Vries, J Fagoaga Mata, S Stein, R De Sanctis, A D'Amico, C Palermo, L Fanelli, M C Scoto, A Mayhew, M Eagle, M Vigo, A Febrer, R Korinthenberg, M de Visser, K Bushby, F Muntoni, N Goemans, M P Sormani, E Bertini, M Pane, E Mercuri.   

Abstract

The aim of our longitudinal multicentric study was to establish the changes on the 6min walk test (6MWT) in ambulant SMA type III children and adults over a 12month period. Thirty-eight ambulant type III patients performed the 6MWT at baseline and 12months after baseline. The distance covered in 6min ranged between 75 and 510m (mean 294.91, SD 127) at baseline and between 50 and 611m (mean 293.41m, SD 141) at 12months. The mean change in distance between baseline and 12months was -1.46 (SD 50.1; range: -183 to 131.8m). The changes were not correlated with age or baseline values (p>.05) even though younger patients reaching puberty, had a relatively higher risk of showing deterioration of more than 30m compared to older patients. Our findings provide the first longitudinal data using the 6MWT in ambulant SMA patients.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  6MWT; Outcome measures; Spinal muscular atrophy

Mesh:

Year:  2013        PMID: 23809874     DOI: 10.1016/j.nmd.2013.06.001

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  16 in total

Review 1.  Spinal muscular atrophy - insights and challenges in the treatment era.

Authors:  Eugenio Mercuri; Maria Carmela Pera; Mariacristina Scoto; Richard Finkel; Francesco Muntoni
Journal:  Nat Rev Neurol       Date:  2020-10-14       Impact factor: 42.937

2.  Two-minute versus 6-minute walk distances during 6-minute walk test in neuromuscular disease: Is the 2-minute walk test an effective alternative to a 6-minute walk test?

Authors:  J W Witherspoon; R Vasavada; R H Logaraj; M Waite; J Collins; C Shieh; K Meilleur; C Bönnemann; M Jain
Journal:  Eur J Paediatr Neurol       Date:  2018-10-23       Impact factor: 3.140

3.  Natural history of 10-meter walk/run test performance in spinal muscular atrophy: A longitudinal analysis.

Authors:  Kristin J Krosschell; Elise L Townsend; Michael Kiefer; Sarah D Simeone; Katelyn Zumpf; Leah Welty; Kathryn J Swoboda
Journal:  Neuromuscul Disord       Date:  2021-08-24       Impact factor: 4.296

Review 4.  Physical exercise training for type 3 spinal muscular atrophy.

Authors:  Bart Bartels; Jacqueline Montes; W Ludo van der Pol; Janke F de Groot
Journal:  Cochrane Database Syst Rev       Date:  2019-03-01

5.  Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial).

Authors:  Marloes Stam; Renske I Wadman; Camiel A Wijngaarde; Bart Bartels; Fay-Lynn Asselman; Louise A M Otto; H Stephan Goedee; Laura E Habets; Janke F de Groot; Marja A G C Schoenmakers; Inge Cuppen; Leonard H van den Berg; W Ludo van der Pol
Journal:  BMJ Open       Date:  2018-07-30       Impact factor: 2.692

6.  Ambulatory function in spinal muscular atrophy: Age-related patterns of progression.

Authors:  Jacqueline Montes; Michael P McDermott; Elizabeth Mirek; Elena S Mazzone; Marion Main; Allan M Glanzman; Tina Duong; Sally Dunaway Young; Rachel Salazar; Amy Pasternak; Richard Gee; Roberto De Sanctis; Giorgia Coratti; Nicola Forcina; Lavinia Fanelli; Danielle Ramsey; Evelin Milev; Matthew Civitello; Marika Pane; Maria Carmela Pera; Mariacristina Scoto; John W Day; Gihan Tennekoon; Richard S Finkel; Basil T Darras; Francesco Muntoni; Darryl C De Vivo; Eugenio Mercuri
Journal:  PLoS One       Date:  2018-06-26       Impact factor: 3.240

7.  Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.

Authors:  Basil T Darras; Claudia A Chiriboga; Susan T Iannaccone; Kathryn J Swoboda; Jacqueline Montes; Laurence Mignon; Shuting Xia; C Frank Bennett; Kathie M Bishop; Jeremy M Shefner; Allison M Green; Peng Sun; Ishir Bhan; Sarah Gheuens; Eugene Schneider; Wildon Farwell; Darryl C De Vivo
Journal:  Neurology       Date:  2019-04-24       Impact factor: 9.910

8.  Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials.

Authors:  Eugenio Mercuri; Richard Finkel; Jacqueline Montes; Elena S Mazzone; Maria Pia Sormani; Marion Main; Danielle Ramsey; Anna Mayhew; Allan M Glanzman; Sally Dunaway; Rachel Salazar; Amy Pasternak; Janet Quigley; Marika Pane; Maria Carmela Pera; Mariacristina Scoto; Sonia Messina; Maria Sframeli; Gian Luca Vita; Adele D'Amico; Marleen van den Hauwe; Serena Sivo; Nathalie Goemans; Petra Kaufmann; Basil T Darras; Enrico Bertini; Francesco Muntoni; Darryl C De Vivo
Journal:  Neuromuscul Disord       Date:  2015-12-03       Impact factor: 4.296

9.  Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.

Authors:  Eugenio Mercuri; James Edward Signorovitch; Elyse Swallow; Jinlin Song; Susan J Ward
Journal:  Neuromuscul Disord       Date:  2016-05-27       Impact factor: 4.296

10.  A continuous repetitive task to detect fatigability in spinal muscular atrophy.

Authors:  Marloes Stam; Renske I Wadman; Bart Bartels; Maureen Leeuw; Henk-Jan Westeneng; Camiel A Wijngaarde; Leonard H van den Berg; W Ludo van der Pol
Journal:  Orphanet J Rare Dis       Date:  2018-09-12       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.